Table 2 Disease activity indices and disease-specific autoantibodies in patients with rheumatic diseases
Systemic sclerosis | n = 120 |
 HAQ-DI, mean (SD) | 0.99 (0.85) |
 SHAQ score, mean (SD) | 0.87 (0.68) |
  Digestive VAS, mean (SD) | 0.54 (0.79) |
  Pulmonary VAS, mean (SD) | 0.63 (1.09) |
  Raynaud’s VAS, mean (SD) | 0.78 (0.78) |
  Digital ulcer VAS, mean (SD) | 0.41 (0.71) |
  Overall disease severity VAS, mean (SD) | 1.05 (0.88) |
 ANA, n (%) | 105 (87.5) |
 Anti-topoisomerase I antibody, n (%) | 49 (40.8) |
 Anti-centromere antibody, n (%) | 23 (19.2) |
Rheumatoid arthritis | n = 120 |
 DAS28 (ESR), mean (SD) | 3.56 (0.12) |
 Patient global health, mean (SD) | 35.21 (2.17) |
 Rheumatoid factor, n (%) | 109 (90.8) |
 Anti-citrullinated protein antibody, n (%) | 76 (63.3) |
Systemic lupus erythematosus | n = 120 |
 SLEDAI-2K, mean (SD) | 6.26 (1.22) |
 ANA, n (%) | 116 (96.7) |
 Anti-Smith antibody, n (%) | 47 (39.2) |
 Anti-ds DNA antibody, n (%) | 90 (75.0) |
 C3, mg/dL, mean (SD) | 74.22 (4.15) |
 C4, mg/dL, mean (SD) | 12.78 (1.15) |
Sjogren’s syndrome | n = 120 |
 ESSDAI, mean (SD) | 1.52 (0.22) |
 ANA, n (%) | 110 (91.7) |
 Anti-SSA/Ro autoantibody, n (%) | 69 (57.5) |
 Anti-SSB/La autoantibody, n (%) | 81 (67.5) |